Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Healthcare | Pharmaceuticals | ARS 800.29T | 112.9x | 8.62 | ARS 20,500 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 385.94T | 10.7x | ARS 1,600 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Johnson & Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 385.94T | 10.7x | 0.11 | ARS 13,775 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Buenos Aires | Healthcare | Pharmaceuticals | ARS 382.11T | 10.6x | 0.31 | ARS 815 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Buenos Aires | Healthcare | Pharmaceuticals | ARS 331.91T | 65.1x | -1.68 | ARS 24,275 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 287.07T | 21.7x | 0.06 | ARS 29,400 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 236.02T | 38.1x | 8.83 | ARS 49,075 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 226.59T | 14.8x | 0.2 | ARS 36,300 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Buenos Aires | Healthcare | Pharmaceuticals | ARS 172.69T | 57.5x | -0.94 | ARS 13,850 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 163.88T | -65.4x | 0.57 | ARS 9,380 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Buenos Aires | Healthcare | Pharmaceuticals | ARS 99.57T | 98.5x | -1.21 | ARS 25,800 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 97.56T | -15.5x | 0.08 | ARS 20,775 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 84.31T | 16.4x | -0.22 | ARS 13,550 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen AR | Buenos Aires | Healthcare | Pharmaceuticals | ARS 27.92T | 24.9x | -0.43 | ARS 19,150 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | Buenos Aires | Healthcare | Pharmaceuticals | ARS 26.54T | 32.5x | 0.19 | ARS 47,025 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorios Richmond | Buenos Aires | Healthcare | Pharmaceuticals | ARS 73.08B | 20.6x | 0.12 | ARS 895 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Instituto Rosenbusch | Buenos Aires | Healthcare | Pharmaceuticals | ARS 4.17B | 4.2x | 0.01 | ARS 98 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |